Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Obesity
is one of the largest health problems facing the world today. Although twin and family studies suggest about two-thirds of
obesity
is caused by genetic factors, only a small fraction of this variance has been unraveled. There are still large numbers of genes to be identified that cause variations in body fatness and the associated diseases encompassed in the metabolic syndrome (MetS). A locus near a sequence tagged site (STS) marker D6S1009 has been linked to
obesity
or body mass index (BMI). However, its genetic entity is unknown. D6S1009 is located in the intergenic region between
SLC35D3
and NHEG1. Here we report that the ros mutant mice harboring a recessive mutation in the Slc35d3 gene show
obesity
and MetS and reduced membrane dopamine receptor D1 (D1R) with impaired dopamine signaling in striatal neurons.
SLC35D3
is localized to both endoplasmic reticulum (ER) and early endosomes and interacts with D1R. In ros striatal D1 neurons, lack of
SLC35D3
causes the accumulation of D1R on the ER to impair its ER exit. The MetS phenotype is reversible by the administration of D1R agonist to the ros mutant. In addition, we identified two mutations in the
SLC35D3
gene in patients with MetS, which alter the subcellular localization of
SLC35D3
. Our results suggest that the
SLC35D3
gene, close to the D6S1009 locus, is a candidate gene for MetS, which is involved in metabolic control in the central nervous system by regulating dopamine signaling.
...
PMID:Mutation of SLC35D3 causes metabolic syndrome by impairing dopamine signaling in striatal D1 neurons. 2455 Jul 37